» Articles » PMID: 30973670

A 17 Gene Panel for Non-small-cell Lung Cancer Prognosis Identified Through Integrative Epigenomic-transcriptomic Analyses of Hypoxia-induced Epithelial-mesenchymal Transition

Overview
Journal Mol Oncol
Date 2019 Apr 12
PMID 30973670
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

As a critical feature of the tumor microenvironment, hypoxia is known to be a potent inducer of tumor metastasis, and it has been proposed that the initial steps in metastasis involve epithelial-mesenchymal transition (EMT). The strong correlation among hypoxia, EMT, and metastasis suggests that integrative assessment of gene expression and the DNA modification program of hypoxia-induced EMT via high-throughput sequencing technologies may increase our understanding of the molecular basis of tumor invasion and metastasis. Here, we present the genomewide transcriptional and epigenetic profiles of non-small-cell lung cancer (NSCLC) cells under normoxic and hypoxic conditions. We demonstrate that hypoxia induces EMT along with dynamic alterations of transcriptional expression and epigenetic modifications in both A549 and HCC827 cells. After training using a dataset from patients with invasive and noninvasive lung adenocarcinomas with an artificial neural network algorithm, a characteristic 17-gene panel was identified, consisting of genes involved in EMT, hypoxia response, glycometabolism, and epigenetic modifications. This 17-gene signature clearly stratified NSCLC patients with significant differences in overall survival across three independent datasets. Our study may be suitable as a basis for further selection of gene signatures to potentially guide prognostic stratification in patients with NSCLC.

Citing Articles

Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.

Di Giovannantonio M, Hartley F, Elshenawy B, Barberis A, Hudson D, Shafique H Cell Genom. 2025; 5(2):100764.

PMID: 39892389 PMC: 11872601. DOI: 10.1016/j.xgen.2025.100764.


Expression Profiles of Hypoxia-Related Genes of Cancers Originating from Anatomically Similar Locations Using TCGA Database Analysis.

Bae H, Jeong K, Yang S, Jun H, Kim K, Chai Y Medicines (Basel). 2024; 11(1).

PMID: 38248716 PMC: 10819830. DOI: 10.3390/medicines11010002.


Combination of tumor asphericity and an extracellular matrix-related prognostic gene signature in non-small cell lung cancer patients.

Zschaeck S, Klinger B, van den Hoff J, Cegla P, Apostolova I, Kreissl M Sci Rep. 2023; 13(1):20840.

PMID: 38012155 PMC: 10681996. DOI: 10.1038/s41598-023-46405-4.


An effective prognostic model for assessing prognosis of non-small cell lung cancer with brain metastases.

Wang R, Zhang X, He C, Guo W Front Genet. 2023; 14:1156322.

PMID: 37124617 PMC: 10143500. DOI: 10.3389/fgene.2023.1156322.


Cell-free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients.

Maansson C, Meldgaard P, Stougaard M, Nielsen A, Sorensen B Mol Oncol. 2023; 17(5):722-736.

PMID: 36825535 PMC: 10158780. DOI: 10.1002/1878-0261.13394.


References
1.
Kitamoto S, Yokoyama S, Higashi M, Yamada N, Matsubara S, Takao S . Expression of MUC17 is regulated by HIF1α-mediated hypoxic responses and requires a methylation-free hypoxia responsible element in pancreatic cancer. PLoS One. 2012; 7(9):e44108. PMC: 3438193. DOI: 10.1371/journal.pone.0044108. View

2.
Ramaswamy S, Ross K, Lander E, Golub T . A molecular signature of metastasis in primary solid tumors. Nat Genet. 2002; 33(1):49-54. DOI: 10.1038/ng1060. View

3.
Yu M, Hon G, Szulwach K, Song C, Zhang L, Kim A . Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell. 2012; 149(6):1368-80. PMC: 3589129. DOI: 10.1016/j.cell.2012.04.027. View

4.
Mimeault M, Batra S . Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med. 2013; 17(1):30-54. PMC: 3560853. DOI: 10.1111/jcmm.12004. View

5.
Hirschhaeuser F, Sattler U, Mueller-Klieser W . Lactate: a metabolic key player in cancer. Cancer Res. 2011; 71(22):6921-5. DOI: 10.1158/0008-5472.CAN-11-1457. View